7th EFIS Tatra Immunology Conference: molecular determinants of T-cell immunity

Bibliography

• BRINKMANN V, DAVIS MD, HEISE CE et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. (2002) 277(24):21453-21457.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4(7):1019-1025.
   PubMed Web of Science ®Google Scholar
• CHIBA K: FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. (2005) 108(3):308-319.
   PubMed Web of Science ®Google Scholar
• FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305(1):70-77.
   PubMed Web of Science ®Google Scholar
• MURRAY CM, HUTCHINSON R, BANTICK JR et al.: Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol. (2005) 1(7):371-376.
   PubMed Web of Science ®Google Scholar
• GUILE SD, BANTICK JR, CHESHIRE DR et al.: Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds. Bioorg. Med. Chem. Lett. (2006) 16(8):2260-2265.
   PubMed Web of Science ®Google Scholar
• EDWARDS CJ: Immunological therapies for rheumatoid arthritis. Br. Med. Bull. (2005) 73-74:71-82.
   PubMed Web of Science ®Google Scholar
• HYRICH KJ, SYMMONS DP, WATSON KD, SILMAN AJ, BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER: Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. (2006) 54(6):1786-1794.
   PubMed Web of Science ®Google Scholar
• VOLL RE, KALDEN JR: Do we need new treatment that goes beyond tumour necrosis factor blockers for rheumatoid arthritis? Ann. NY Acad. Sci. (2005) 1051:799-810.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, FOEY AD, FELDMANN M: The importance of T cell interactions with macrophages in rheumatoid cytokine production. Curr. Top. Microbiol. Immunol. (2006) 305:177-194.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, SCHMITT E: Regulatory T-cells in antitumour therapy: isolation and functional testing of CD4+CD25+ regulatory T-cells. Methods Mol. Med. (2005) 109:285-296.
   PubMedGoogle Scholar
• STASSEN M, FONDEL S, BOPP T et al.: Human CD25+ regulatory T cells: two subsets defined by the integrins α4β7 or α4β1 confer distinct suppressive properties upon CD4+ T helper cells. Eur. J. Immunol. (2004) 34(5):1303-1311.
   PubMed Web of Science ®Google Scholar
• KEIR ME, LIANG SC, GULERIA I et al.: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. (2006) 203(4):883-895.
   PubMed Web of Science ®Google Scholar
• SEDDIKI N, SANTNER-NANAN B, MARTINSON J et al.: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. (2006) 203(7):1693-1700.
   PubMed Web of Science ®Google Scholar
• LUI W, PUTNAM AL, XU-YU Z et al.: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J. Exp. Med. (2006) 203(7):1701-1711.
   PubMed Web of Science ®Google Scholar
• BOTTINI N, MUSUMECI L, ALONSO A et al.: A functional variant of lymphoid tyrosine phosphatase is associated with Type 1 diabetes. Nat. Genetics (2004) 36(4):337-338.
   PubMed Web of Science ®Google Scholar
• BOTTINI N, VANG T, CUCCA F, MUSTELIN T: Role of PTPN22 in Type 1 diabetes and other autoimmune diseases. Semin. Immunol. (2006) 18(4):207-213.
   PubMed Web of Science ®Google Scholar
• SCHMIDT U, BOUCHERON N, UNGER B, ELLMEIER W: The role of Tec family kinases in myeloid cells. Int. Arch. Allergy Immunol. (2004) 134(1):65-78.
   PubMed Web of Science ®Google Scholar
• STEFANOVA I, HEMMER B, VERGELLI M, MARTIN R, BIDDISON WE, GERMAIN RN: TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. (2003) 4(3):248-254.
   PubMed Web of Science ®Google Scholar
• SIROVA M, STROHALM J, SUBR V et al.: Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol. Immunother. (2006) (In Press).
   PubMedGoogle Scholar
• DHODAPKAR MV, KRASOVSKY J, OSMAN K, GELLER MD: Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. (2003) 198(11):1753-1757.
   PubMed Web of Science ®Google Scholar
• DHODAPKAR MV, GELLER MD, CHANG DH et al.: A reversible defect in natural killer T cell function characterizes the progression of the premalignant to malignant multiple myeloma. J. Exp. Med. (2003) 197(12):1667-1676.
   PubMed Web of Science ®Google Scholar
• CHANG DH, OSMAN K, CONNOLLY J et al.: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. (2005) 201(9):1503-1517.
   PubMed Web of Science ®Google Scholar
• IMAI Y, KUBA K, RAO S et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005) 436(7047):112-116.
   PubMed Web of Science ®Google Scholar
• KUBA K, IMAI Y, RAO S et al.: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. (2005) 11(8):875-879.
   PubMed Web of Science ®Google Scholar
• MESTECHY J, MOLDOVEANU Z, RUSSELL MW: Immunologic uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. (2005) 53(5):208-214.
   PubMed Web of Science ®Google Scholar